How do peptides work?
How do peptides work? These mechanism articles are the how behind the what. If you want to understand what a GLP-1 dual agonist actually does after injection, why a growth hormone peptide works with your pituitary instead of around it, or which receptor a molecule binds — this is that shelf.
Written to be understood like you're fifteen, sourced from the primary literature, and honest wherever the mechanism is still a hypothesis rather than settled science.
148 articles on this topic
-
KLOW Peptide Stack: Four Peptides in One Vial
A “stack” just means taking more than one peptide at a time. KLOW is one that comes already mixed — four peptides in a single prescribed vial, so there is nothing for you to assemble.
-
Tesamorelin Half-Life Is Measured in Minutes
Tesamorelin leaves the bloodstream quickly, but the signal it starts can last much longer. That difference explains why trials used it once daily and why providers follow IGF-1 instead of watching the clock.
-
Tirzepatide Pills Don't Exist. Here's What Does
There is no oral tirzepatide, either as a brand product or a validated compounded pill. Real GLP-1 tablets contain semaglutide or orforglipron, which are different medicines.
-
No Shortcut: The Peptide FDA Approval Process
Mimrylo’s August 2026 approval is a useful look at the whole path: permission to begin human studies, three trial phases, a full application, manufacturing review, and a label limited to one use.
-
Kisspeptin for Men: What the Studies Really Show
Kisspeptin may affect reproductive hormones and sexual response in men. The evidence is promising but small, and it does not establish a standard dose or long-term treatment plan.
-
Semaglutide and Heart Health: What Studies Show
Semaglutide has been linked to fewer major cardiovascular events in a specific high-risk group, and to better symptoms in one type of heart failure. The numbers are meaningful, but they do not apply to every heart or every formulation.
-
Semaglutide for Heart Failure Now Has ESC Support
Europe's 2026 heart-failure guideline now says semaglutide or tirzepatide should be considered for symptomatic patients with obesity and an ejection fraction of at least 45%. The recommendation is about symptoms, walking capacity, and quality of life—not proof that semaglutide prevents death.
-
Tirzepatide vs Ozempic: What You're Comparing
Ozempic is a brand of semaglutide, approved for type 2 diabetes. Tirzepatide is a different molecule with its own brands — so the comparison most people want is between two drugs, not a drug and a label.
-
What Is Sermorelin Used For? A Plain Answer
Sermorelin was approved once, for children who were not growing. Adults are prescribed it today for sleep, body composition and recovery — uses that rest on a handful of small studies.
-
Does CJC-1295 Ipamorelin Work? Evidence Review
The combination has no clinical trial of its own. Separate studies show that CJC-1295 and ipamorelin can raise growth hormone signals, but they do not establish predictable sleep, recovery, muscle, or fat-loss results from the blend.
-
GLP-1 Patches: Do They Work?
GLP-1 patches sold online are usually supplement stickers, not semaglutide or tirzepatide. Ordinary patches cannot move these large peptide drugs across intact skin in a predictable dose.
-
Semaglutide and Aging: The New Study Is in Mice
A new Nature study found longer life and better physical function in old female mice given semaglutide. It did not test people, so it cannot tell us that semaglutide slows human aging or adds years to human life.
-
Semaglutide L-Carnitine: What the Additive Means
Some compounders add L-carnitine for its role in fat metabolism. The rationale is real biology, but no human trial shows that mixing it with semaglutide improves weight-loss outcomes.
-
Semax for ADHD: What the Evidence Actually Shows
Semax has not been tested in a human ADHD trial. The attention claims come from a small study in healthy volunteers, neurological research, and a biological hypothesis—not evidence that it treats ADHD.
-
Tesamorelin for Women: Evidence and Menopause
Tesamorelin for women has limited female-specific evidence: pivotal trials enrolled 84%–86% men, and no trial was designed for menopause-related abdominal change. Hormone therapy, pregnancy, glucose and IGF-1 all change the prescribing conversation.
-
Tesamorelin Injections: Sites, Timing, and Storage
Tesamorelin is injected under the skin once daily. The abdomen, site rotation, timing, device format, and storage instructions all matter—and they are not identical across branded and compounded formulations.
-
BPC-157 Arginate vs Acetate: What Changes?
Arginate and acetate name salt forms of the same 15-amino-acid peptide. The counter-ion may change formulation properties, but no published in-vivo comparison shows that one produces better clinical outcomes.
-
Does Tesamorelin Work? What the Trials Show
Tesamorelin reduced visceral abdominal fat in two large phase 3 trials, but those studies involved adults with HIV-associated lipodystrophy. The evidence does not establish it as a general weight-loss medication or promise the same result for every patient.
-
DSIP Benefits: What the Human Evidence Shows
DSIP has been studied most directly for sleep, but the human findings are small, old and mixed. Signals involving ACTH, chronic pain and withdrawal are preliminary rather than established benefits.
-
Is Semaglutide a GLP-1? What the Class Means
Yes. Semaglutide is a GLP-1 receptor agonist and an engineered peptide. Those labels describe two different things: the receptor it activates and the structure of the medication.
Page 4 of 8 · 148 articles